Finding legitimacy for the role of budget impact in drug reimbursement decisions.
about
Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making CriterionProspects of risk-sharing agreements for innovative therapies in a context of deficit spending in bulgaria.Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in BulgariaRelationship between financial impact and coverage of drugs in Australia.Administrative Process and Criteria Ranking for Drug Entering Health Insurance List in Iran-TOPSIS-Based Consensus ModelMulti-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.Efficiency or equity: value judgments in coverage decisions in Thailand.PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.Sustainable Financing of Innovative Therapies: A Review of Approaches.Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System.Adoption of trastuzumab for breast cancer in four emerging countries in the use of health technology assessment: a case study.Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).Health Technology Assessment and Appraisal of Therapies for Rare Diseases.Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
P2860
Q31125979-89A0109E-E2E4-44E5-98CF-AE8DA110F8F4Q35522232-67A522D0-2709-4706-B63D-DE9C7887BAE1Q36110773-7935AE8D-0ACE-4610-8F98-50C9DAFA92ACQ36618422-AFE7F7D1-2403-4E08-A5D0-9AA435EF1A4CQ36638320-676EFD50-BF36-43EC-BF63-3FD02AFC9188Q37178151-09EC7648-CAB2-40FD-B0A6-9BB6DFFF6029Q37297978-731EE2F6-3E6F-42C7-9360-82EEFBE8496EQ38031244-5D3552DE-F97D-40D6-A37A-052C72AEE2F3Q38681395-C187BF51-AB7A-4017-94CB-09FF0D527AC1Q38850678-61C5E7AB-6EE6-4510-B725-409BBE6D9C7FQ39271327-AF3DCFAE-D30F-42DB-8168-B76344FF2582Q39664372-71736333-08FC-4BB9-A522-684D5632A1BFQ43620093-A13B3B27-1FFE-4948-B67F-BAA2C716DC31Q47299182-D7F4DFC1-6342-4EC9-B0F2-9AF3EC7CC4EDQ47583991-F4B114D1-BC5F-414B-A2F1-AAB546C5D113Q53175599-A625D669-8366-4048-BBA4-80F2616D118A
P2860
Finding legitimacy for the role of budget impact in drug reimbursement decisions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Finding legitimacy for the role of budget impact in drug reimbursement decisions.
@en
Finding legitimacy for the role of budget impact in drug reimbursement decisions.
@nl
type
label
Finding legitimacy for the role of budget impact in drug reimbursement decisions.
@en
Finding legitimacy for the role of budget impact in drug reimbursement decisions.
@nl
prefLabel
Finding legitimacy for the role of budget impact in drug reimbursement decisions.
@en
Finding legitimacy for the role of budget impact in drug reimbursement decisions.
@nl
P2093
P2860
P1476
Finding legitimacy for the role of budget impact in drug reimbursement decisions
@en
P2093
Elly A Stolk
Joshua P Cohen
Maartje G H Niezen
P2860
P356
10.1017/S0266462309090072
P577
2009-01-01T00:00:00Z